Published in Med J Aust on March 15, 2004
Patient safety requires a new way to publish clinical trials. PLoS Clin Trials (2006) 2.35
A systematic review of complex system interventions designed to increase recovery from depression in primary care. BMC Health Serv Res (2006) 1.52
Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials (2009) 1.44
Interaction trees with censored survival data. Int J Biostat (2008) 1.31
Chronic non-specific low back pain - sub-groups or a single mechanism? BMC Musculoskelet Disord (2008) 1.20
Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis--funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. Crit Care (2008) 1.10
Pre-referral rectal artesunate in severe malaria: flawed trial. Trials (2011) 1.10
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol (2012) 1.03
Evaluation of heterogeneity in pharmacotherapy trials for drug dependence: a Bayesian approach. Am J Drug Alcohol Abuse (2009) 1.01
Bench-to-bedside review: the evaluation of complex interventions in critical care. Crit Care (2008) 1.00
Outcome based subgroup analysis: a neglected concern. Trials (2009) 0.97
A review of calcium supplements and cardiovascular disease risk. Adv Nutr (2012) 0.94
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med (2011) 0.89
Assessing Heterogeneity of Treatment Effects: Are Authors Misinterpreting Their Results? Health Serv Res (2010) 0.85
Assessment of pre- and post-methionine load homocysteine for prediction of recurrent stroke and coronary artery disease in the Vitamin Intervention for Stroke Prevention Trial. Atherosclerosis (2007) 0.85
The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making (2014) 0.84
Critical care trial design and interpretation: a primer. Crit Care Med (2010) 0.83
Statistical pitfalls in medical research. Malawi Med J (2008) 0.80
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract (2011) 0.78
The influence of baseline marijuana use on treatment of cocaine dependence: application of an informative-priors bayesian approach. Front Psychiatry (2012) 0.77
A reader responds to "The myth of equipoise in phase 1 clinical trials". Medscape J Med (2008) 0.75
Moderators of treatment response to trauma-focused cognitive behavioral therapy among youth in Zambia. J Child Psychol Psychiatry (2016) 0.75
Allocation concealment and blinding: when ignorance is bliss. Med J Aust (2005) 2.85
Determining the sample size in a clinical trial. Med J Aust (2002) 2.51
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol (2010) 2.23
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J (2006) 2.12
Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust (2003) 2.06
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet (2009) 1.88
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA (2012) 1.71
Statistical methods in clinical trials. Med J Aust (2003) 1.47
Putting results of a clinical trial into perspective. Med J Aust (2007) 1.42
Randomisation in clinical trials. Med J Aust (2002) 1.40
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol (2008) 1.26
Specifying objectives and outcomes for clinical trials. Med J Aust (2002) 1.24
Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care (2008) 1.18
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J (2009) 1.17
Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. Med Care (2009) 1.12
Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Med J Aust (2005) 1.08
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes (2012) 1.08
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care (2011) 1.08
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol (2011) 1.02
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst (2011) 0.96
Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care (2012) 0.95
Baseline data in clinical trials. Med J Aust (2003) 0.95
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes (2013) 0.90
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc (2013) 0.89
Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry (2012) 0.89
Multiple analyses in clinical trials: sound science or data dredging? Med J Aust (2004) 0.89
Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. Hum Reprod (2002) 0.88
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol (2009) 0.87
Generalising the results of trials to clinical practice. Med J Aust (2004) 0.86
Interpreting the results of a clinical trial. Med J Aust (2007) 0.86
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab (2012) 0.85
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia (2014) 0.83
Balloon warming time is the strongest predictor of late pulmonary vein electrical reconnection following cryoballoon ablation for atrial fibrillation. Heart Rhythm (2013) 0.82
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J (2012) 0.82
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study. Clin Chem Lab Med (2012) 0.79
An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovasc Ther (2011) 0.79
An evidence based clinical aid for cardiovascular disease--what do GPs think? Aust Fam Physician (2005) 0.79
Balancing the outcomes: reporting adverse events. Med J Aust (2004) 0.78
Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? ANZ J Surg (2003) 0.78
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2014) 0.78
Identification of the sentinel lymph node in the SNAC-1 trial. ANZ J Surg (2014) 0.77
Subgroup analysis: application to individual patient decisions. Med J Aust (2004) 0.77
Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial. Int J Cardiol (2013) 0.77
Recruitment to randomised studies. Med J Aust (2003) 0.77
Statistical rigour is essential to clinical prediction. ANZ J Surg (2007) 0.75
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium? J Am Coll Cardiol (2014) 0.75
Sharp v Port Kembla RSL Club: establishing causation of laryngeal cancer by environmental tobacco smoke. Med J Aust (2002) 0.75
Specifying interventions in a clinical trial. Med J Aust (2002) 0.75
Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiol (2006) 0.75
Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002. Med J Aust (2003) 0.75
Decision making in older patients with advanced cancer: does doctor know best? Med J Aust (2012) 0.75
Flow of participants in randomised studies. Med J Aust (2003) 0.75
Development of a spreadsheet for the calculation of new tools to improve the reporting of the results of medical research. Med Inform Internet Med (2006) 0.75
Forming networks for research: proposal for an Australian clinical trials alliance. Med J Aust (2013) 0.75
Evaluation of patient preferences towards treatment during extended hours for patients receiving radiation therapy for the treatment of cancer: a time trade-off study. Radiother Oncol (2009) 0.75
The role of statin therapy in patients with lower vascular risk. Med J Aust (2012) 0.75
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia (2015) 0.75
Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2015) 0.75
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem (2017) 0.75
Making sense of trial results: outcomes and estimation. Med J Aust (2004) 0.75